| Title | [Oligonucleotide therapeutics - an emerging novel class of compounds.] | | Author(s) | Wacheck V | | Institution | Abteilung für Experimentelle Onkologie/Molekulare Pharmakologie, Universitätsklinik für Klinische Pharmakologie, Medizinische Universität Wien, Wien, Austria, Volker.Wacheck@meduniwien.ac.at. | | Source | Wien Med Wochenschr 2006 Sep; 156(17-18):481-7. | | Abstract | Oligonucleotide therapeutics are short, single- or double-stranded DNA or RNA molecules consisting of strands of 10-50 nucleotides. By targeted modulation of gene expression oligonucleotides provide the chance of targeting diseases at their molecular level. Within this novel emerging class of compounds oligonucleotide therapeutics are discriminated by their structure, function and mode of action. While antisense oligonucleotides, ribozymes and siRNAs suppress the expression of a protein by complementary hybridizing with their target mRNA, aptamers bind like antibodies to their target protein and thereby inhibit its function. Immunostimulatory oligonucleotides are due to sequence motifs within their nucleotide sequence able to trigger a therapeutic exploitable immune response. Currently, there are only two oligonucleotide therapeutics approved by the FDA, namely the antisense oligonucleotide Fomivirsen and the aptamer Macugen. In this review the mode of action of the diverse oligonucleotide therapeutics and their current status in clinical development will be discussed. | | Language | ger | | Pub Type(s) | Journal Article
| | PubMed ID | 17041803 |
|
